



Published in final edited form as:

J Burn Care Res. 2017 ; 38(6): 396–402. doi:10.1097/BCR.0000000000000575.

Safety of Nebulized Epinephrine in Smoke Inhalation Injury

Guillermo Foncerrada, MD^{a,b}, Francisco Lima, MD^{a,b}, Robert P. Clayton, BS^{a,b}, Ronald P. Micak, PhD^{a,b}, Perenlei Enkhbaatar, MD, PhD^{a,b}, David N. Herndon, MD^{a,b}, and Oscar E. Suman, PhD^{a,b}

^aDepartment of Surgery, University of Texas Medical Branch Galveston, Galveston, Texas

^bShriners Hospitals for Children, Galveston, Texas

Abstract

This pilot study was conducted to profile safety of nebulized racemic epinephrine when used as a therapy for smoke inhalation injury in severely burned children. We enrolled 16 patients who were 7 to 19 years of age ([mean \pm SD] 12 ± 4 years) with burns covering over 30% of the total body surface area ($55 \pm 17\%$) and smoke inhalation injury, as diagnosed by bronchoscopy at burn center admission. Patients were randomized to receive either standard of care (SOC; $n = 8$), which consisted of nebulized acetylcysteine, nebulized heparin, and nebulized albuterol, or to receive SOC plus nebulized epinephrine ($n = 8$). Primary endpoints were death, chest pain, and adverse changes in cardiopulmonary hemodynamics (arrhythmia, arterial blood pressure, electrocardiographic [ST segment] changes, and peak inspiratory pressure). Additional endpoints included total days on ventilator, pulmonary function, and physiological cardiopulmonary measurements at ICU discharge. No adverse events were observed during or after the nebulization of epinephrine, and no deaths were reported that were attributable to the administration of nebulized epinephrine. The groups did not significantly differ with regard to age, sex, burn size, days on ventilator, pulmonary function, or cardiopulmonary fitness. Results of this pilot trial indicate epinephrine to be safe when administered to pediatric burn patients with smoke inhalation injury. Current data warrant future efficacy studies with a greater number of patients.

Keywords

Burns; smoke inhalation injury; nebulized epinephrine

INTRODUCTION

Burns are often the result of childhood accidents. The American Burn Association estimates that 95% of burn injuries are accidents,¹ leading to 265 000 deaths around the world annually, mainly in low- and middle-income countries.² According to the most recent National Burn Repository (NBR), the percentage of patients with only smoke inhalation

Address correspondence to: Oscar E. Suman, PhD, Shriners Hospitals for Children, 815 Market Street, Galveston, Texas 77550, USA; Tel: +1 409 770 6557, Fax: +1 409 770 6919. oesuman@utmb.edu.

Conflicts of Interest

The authors declare no conflicts of interest.

injury is 1.1% and with smoke inhalation injury plus burns is almost 10%.¹ Others have reported the frequency of smoke inhalation injury plus burns is as high as 19.6%^{3,4} among patients admitted to burn centers.

Additionally, in the age groups of >60 years of age, case fatality greatly increases at the level of 20% TBSA with inhalation injury and above as compared to <60 years of age.¹

Despite recent advances in critical care and the management of burn patients, smoke inhalation injury continues to substantially increase the morbidity and mortality after burns.⁵

In a classic study published in 1987 that described a large clinical experience at the U.S. Army Institute of Surgical Research, the predicted mortality among patients with burns was 20% higher when inhalation injury was present than when it was not; if secondary pneumonia developed, mortality was 60% higher.⁶

Dr. Sheridan published in 2016 in the *New England Journal of Medicine* that the complex physiological processes underlying inhalation injury remain poorly understood and specific therapeutic interventions remain ineffective.⁷

Smoke inhalation injury leads to airway lumen narrowing or occlusions through bronchospasm, increased mucus secretion, formation of airway casts, and increased airway blood flow. Augmented airway blood flow, in particular, plays a critical role in the pathogenesis of acute lung injury after smoke inhalation.^{8,9} A 20-fold increase in bronchial blood flow occurs immediately following inhalation injury, resulting in lung edema and pulmonary transvascular fluid flux.^{10,11,12} Moreover, increased plasma exudates in the airway play a role in the formation of obstructive casts,¹³ which diminish pulmonary function, and may cause atelectasis, pneumonia, and barotrauma respiratory distress.^{14,15}

The successful results obtained with the ligation of the bronchial artery in sheep, are not feasible in humans. Therefore, we decided to pursue a pharmacological approach that would mimic the effects of ligation of the bronchial artery.

The major pathophysiology seen following inhalation injury arises from microvascular changes.¹⁶ Combined thermal and inhalation injury leads to upregulation of cytokines such as IL-1 in lung tissue. Both IL-1 and endotoxin activate NF- κ B, which induces the synthesis of iNOS and iNOS catalyses. This leads to the production of large amounts of the vasodilator nitric oxide¹⁷ to produce bronchial vasodilation.

Reactive oxygen species combine with nitric oxide (a potent vasodilator), constitutively formed in the endothelium, to form reactive nitrogen species (RNS).¹⁸

The latter produce edema in the burned area by increasing the microvascular pressure and permeability to protein.¹⁹

Successful treatment of patients with burns and smoke inhalation injury largely depends on the prevention of airway occlusion and ventilator induced lung injury while providing necessary mechanical ventilator support until needed. Thus, a single pharmacological agent that can decrease bronchospasm, reduce airway wall edema, and prevent the airway

transudation would be highly valuable for this purpose. The agent should also target the airway obstruction that results from augmented airway blood flow. Epinephrine is a non-specific adrenergic receptor agonist that induces vasoconstriction via alpha-one receptor stimulation and bronchodilation via beta-two agonist effects.²⁰ Vasoconstriction can reduce the blood flow to glands and decrease mucus secretion. Thus, administering nebulized epinephrine into the airway may be an effective way to moderate most of the detrimental airway changes after smoke inhalation injury. Additional advantages of epinephrine are its low cost and availability in powder and liquid forms, which can be easily aerosolized.

We have previously investigated the efficacy and safety of nebulized epinephrine in a well-characterized smoke inhalation injury ovine model. We found that epinephrine significantly reduced pulmonary transvascular fluid flux to water and protein when compared with the control treatment.²¹ It also reduced airway blood flow and attenuated pulmonary dysfunction.²² Given the beneficial effects of nebulized epinephrine in this experimental model, we conducted this pilot study to test the safety of nebulized epinephrine when used as a therapy for inhalation injury in burn patients.

METHODS

Patients and Study Design

This prospective randomized study was conducted in children admitted to our burn center from September 2014 to September 2016. The study protocol was approved by the Institutional Review Board (University of Texas Medical Branch, Galveston, TX). Parents or legal guardians provided informed consent prior to enrollment. To be included in the study, all children must have been between 7 and 19 years of age. This age range was selected based on our previous experience in administering the Six-Minute Walk Test (6MWT) and use guidelines suggested by the American Thoracic Society (ATS) for pulmonary function tests; children that are 7 years or older can properly follow the instructions to do these tests, and reliable results can be obtained. Other inclusion criteria were thermal burns (flame alone or combination of flame and electrical) covering more than 30% of the total body surface area (TBSA), confirmed inhalation injury, and admission to the burn unit within 96 hours of injury. Exclusion criteria were pregnancy and pre-existing use of alpha- or beta-receptor blocking agents. Inhalation injury was confirmed by bronchoscopy in all patients. Bronchoscopic findings had to have included soot deposits, erythema, edema, mucosal blisters and erosion, and hemorrhage. At admission, height and weight were measured.

Primary endpoints were adverse events (arrhythmia, increase in blood pressure, shock, dyspnea, ST segment changes, chest pain, and death). Secondary endpoints were time on ventilator (LOV), length of stay in the ICU (LOS), pulmonary function (forced expiratory volume in the first second [FEV1]), percent predicted FEV1, forced vital capacity (FVC), percent predicted FVC, pneumonia, pulmonary mechanics (tidal volume, peak inspiratory pressure, positive end expiratory pressure), albuterol doses required, and distance covered in the 6MWT.

Treatment Groups and Standard of Care (SOC)

Patients were randomly allocated to either of the following groups.

1. SOC group
 - Albuterol 2.5 mg in 3 ml of saline, nebulized as needed for wheezing over 7 days
 - Acetylcysteine (20% solution), 3 ml nebulized every 4 hours over 7 days
 - Heparin [5,000 units/3 ml], 3 ml solution nebulized every 4 hours over 7 days
 - Percussion and postural drainage (chest physical therapy), routine every 4 hours, mechanical
2. 2) Intervention group (SOC plus epinephrine [SOC+EPI])
 - Racemic epinephrine (2.25% solution, 0.5 mL in 3 mL of saline) administered every 4 hours for 7 consecutive days

For the nebulization, a respiratory therapist adjusted the settings and characteristics of the ventilator and set the nebulizer according to previously published recommendations.²³ This included the following.

- Suctioning of endotracheal and airway secretions
- Placing drug in nebulizer to correct fill volume
- Placing nebulizer in the inspiratory line 18 inches from the patient y-piece
- Turning off flow-by or continuous flow during nebulization
- Adjusting the inspiratory time for a longer cycle time
- Setting gas flow to nebulizer at 8 L/min
- Using continuous flow from an external gas source
- Adjusting ventilator volume or pressure limit to compensate for additional flow
- Tapping nebulizer periodically until nebulizer begins to sputter
- Monitoring patient for adverse outcomes (see primary outcomes)
- Assessing outcome and documenting findings

Since the ventilators used in the study did not have a built-in nebulizer for nebulization strictly during inspiration, we continuously nebulized the medication at the prescribed dose and in the manner delineated above. To reduce the amount of drug that may have been deposited in the ventilator tubes rather than in the airway of the patients, we followed all the recommendations given by Dhand²⁴ per the bullets above.

Length of Time on Ventilator, Length of Stay, Presence of Pneumonia, and Albuterol Doses

The total days of mechanical ventilation, LOS, LOS/TBSA, LOS/TBSA third degree burn, and the presence of pneumonia were recorded as reported on the medical records. The total number of albuterol doses needed during the first 7 days of hospitalization were also recorded.

Functional Capacity Testing

Upon ICU discharge, patients' physical functional capacity was assessed via the 6MWT. The 6MWT was performed indoors along a long, flat, straight, and enclosed corridor that is seldom traveled and has a hard surface. The walking course was 30 m in length and had turnaround points that were marked with cones (such as orange traffic cones) according to the American Thoracic Society guidelines.²⁵ Briefly, patients were instructed to walk at their fastest pace and to cover the longest possible distance over a 6-minute period while under the supervision of trained clinical research assistants.

Pulmonary Function Testing and Ventilator Variables

Lung volumes were assessed during scheduled outpatient visits within the first week of discharge from the ICU. The pulmonary function testing (PFT) study variables included FVC, FEV1, and diffusing capacity of the lungs for carbon monoxide (DLCO). All spirometry measurements were performed using a PFT system (Medical Graphics PF/DX, St. Paul, MN) with the subject in an upright position. Lung volumes were corrected for body temperature and atmospheric pressure. Subjects correctly performed at least 2 practice forced maximal inhalations and exhalations before any spiograms were recorded. All expected values were obtained using validated general population equations, and normal predicted values were obtained from Knudson et al.²⁶ The procedures were performed in accordance with the guidelines from the American Thoracic Society.²⁷ The criteria that were used to determine whether the subjects performed the maximal spirometry maneuvers included 1) appropriate flow-volume curve shape; 2) lack of artifacts in results such as coughing, premature termination of the test, expiratory effort, or delayed onset of measurement; 3) sustained expiration for a minimum of 3 seconds; and 4) performance deemed satisfactory by the tester.²⁸ Ventilator parameters such as tidal volume, peak inspiratory pressure, and positive end expiratory pressure were obtained from the electronic medical record.

Adverse Events

The patients were closely observed during the administration of the drug by the respiratory therapist as well as by the ICU nurse. Heart rate, electrocardiogram trace (ST segment change), arrhythmia, blood pressure, and oxygen saturation were constantly monitored to detect any possible adverse events directly related to the nebulization of epinephrine.

Statistical Analysis

Measurements were transferred to an encrypted spreadsheet, and statistical analyses were performed using Excel (Microsoft, Richmond, VA, USA). Normally distributed measurements are presented as mean \pm standard deviation. Continuous measurements such

as age, TBSA burn, TBSA full-thickness burn, height, weight, LOS, ventilator days, FEV1, FEV1%, FVC, FVC%, and DLCO were compared between groups using a Student's t-test for matched pair samples. Sex was compared using a Chi-square test. Significance was accepted at $p < 0.05$.

RESULTS

Patient Characteristics

Sixteen patients were enrolled, 8 in the SOC group (5 males and 3 females) and 8 in the SOC+EPI group (6 males and 2 females) (Table 1). Mean age was 13 ± 4 years in the SOC group and 11 ± 2 years in the SOC+EPI ($P = 0.481$). The groups did not statistically significantly differ with respect to percent TBSA burned ($58 \pm 14\%$ for SOC vs $49 \pm 18\%$ for SOC+EPI, $P = 0.277$), percent TBSA full-thickness burn ($51 \pm 20\%$ for SOC vs $43 \pm 24\%$ for SOC+EPI, $P = 0.502$), height (148.6 ± 19.5 cm for SOC vs 144.8 ± 19.2 cm for SOC+EPI, $P = 0.713$), or weight (52.3 ± 21.7 kg for SOC vs 42.1 ± 14.9 kg for SOC+EPI, $P = 0.306$).

Adverse Events and Mortality

The main goal of the study was to determine the safety of the nebulized epinephrine for children with smoke inhalation injury. Neither group had any adverse event such as arrhythmia, shock, dyspnea, ST segment changes, or chest pain that was related to the administration of nebulized epinephrine. In addition, there were no deaths during acute hospitalization.

Time on Ventilator, Length of Stay, Presence of Pneumonia, and Albuterol Doses

LOV was 7.5 ± 5.5 days in the SOC+EPI group and 10.1 ± 7.6 days in the SOC group ($P = 0.470$) (Table 2). LOS was 47.4 ± 44.4 days in the SOC+EPI group and 55.2 ± 25.6 days in the SOC+EPI group ($P = 0.687$). LOS normalized to TBSA burned was similar between groups (LOS/TBSA burned = 0.9), as was LOS normalized to TBSA full-thickness burn (LOS/TBSA full-thickness burn = 1). Pneumonia occurred in 4 of the 8 SOC patients (50%) and only 3 of the 8 SOC+EPI patients (37.5%). The number of doses of albuterol required was 6.7 ± 9 and 5.1 ± 8 for SOC and SOC+EPI patients, respectively ($P = 0.748$).

Functional Capacity Testing, Pulmonary Function Testing, and Ventilator Variables

The distance walked in the 6MWT was 253 ± 268 ft for the SOC group and 588 ± 384 ft for the SOC+EPI group ($P = 0.079$) (Table 2). PFT variables were comparable in the two groups: FEV1 (2.1 ± 0.9 L for SOC vs 2.4 ± 1.79 L for SOC+EPI, $P = 0.787$), percent predicted FEV1 ($86.3 \pm 85\%$ for SOC vs $90.6 \pm 31.5\%$ for SOC+EPI, $P = 0.837$), FVC (2.5 ± 1.2 L for SOC vs 3.1 ± 1.9 L SOC±EPI, $P = 0.735$), and percent predicted FVC ($87.3 \pm 9.4\%$ for SOC vs $97.1 \pm 23\%$ for SOC+EPI, $P = 0.554$). DLCO was also similar in both groups (12.6 ± 4 mL/min/mm Hg for SOC vs 12.7 ± 10 mL/min/mm Hg for SOC+EPI, $P = 0.991$). The percent predicted DLCO was comparable in both groups as well ($74.5 \pm 23\%$ for SOC vs $147 \pm 114\%$ for SOC+EPI, $P = 0.692$) (Table 3). Tidal volume (432 ± 209 mL for SOC vs 338 ± 138 mL for SOC+EPI, $P = 0.371$), peak inspiratory pressure (29 ± 2 mm Hg for SOC vs 23 ± 9 mm Hg for SOC+EPI, $P = 0.119$), and positive end expiratory

pressures were also similar between groups (8.0 ± 0.4 mm Hg for SOC vs 7.0 ± 2.1 for SOC +EPI, $P= 0.262$) (Table 2).

DISCUSSION

The major finding of the study was that the nebulization of racemic epinephrine in children 7 to 19 years old with smoke inhalation injury was safe, as no adverse effects such as an increase in heart rate or mean arterial blood pressure, arrhythmia, elevation of ST segment, or death were observed during or after the nebulization period.

Although determining the efficacy of nebulized epinephrine was not a primary goal of this study because of the limited numbers of patients in each arm, we were able to investigate some key variables, for example, LOV, as secondary endpoints. It is premature to draw any conclusion regarding the efficacy of nebulized epinephrine given the lack of any significantly differences in the variables measured and the limited number of enrolled patients. Nevertheless, our data suggest that patients treated with epinephrine may have experienced improved physical endurance but there are differences between the groups regarding age, weight and burn size that are clinically significant and this may explain the results in the distance walked during the 6MWT. The difference of the distance walked could also be related to the decrease in LOV and LOS. It has previously been reported that muscle loss increases with sustained length of stay in the ICU, a condition known as ICU-acquired weakness that is related to inactivity in the ICU plus the hypermetabolic state of critically ill patients.^{29,30} It is possible that the decrease in ICU days resulted in better daily activities (i.e., eating, bathing, dressing, toileting, and walking).³¹ The 6MWT is a valid outcome in ICU survivors; it has been used in a prior ICU randomized controlled trial³² and predicts patient-centered outcomes including mortality and quality of life.³³

Factors reducing the 6MWD: Shorter height, older age, higher body weight, female sex, impaired cognition, a shorter corridor (more turns), pulmonary disease (COPD, asthma, cystic fibrosis, interstitial lung disease), cardiovascular disease (angina, myocardial infarction, congestive heart failure, stroke, transient ischemic attack, peripheral vascular disease), musculoskeletal disorders (arthritis, ankle, knee, or hip injuries, muscle wasting, etc.)

Factors increasing the 6MWD: Taller height (longer legs), male sex, high motivation, a patient who has previously performed the test, medication for a disabling disease taken just before the test, and oxygen supplementation in patients with exercise-induced hypoxemia.²⁵

The results of this pilot study showing that nebulized epinephrine is well tolerated without any adverse effects and may have beneficial effects in burn patients with smoke inhalation injury mandate larger prospective randomized clinical studies on efficacy. The use of nebulized epinephrine for the treatment of smoke inhalation injury is innovative, as no studies have investigated the local use of epinephrine in the airway to treat smoke inhalation injury in the pediatric population. The dual action of epinephrine (alpha one and beta two adrenergic receptor agonist) enables it to counter multiple pathophysiologic changes that develop in the airway after an inhalation injury. For example, it produces bronchial

vasoconstriction, and it diminishes the formation of mucus casts by reducing the blood flow to the mucus glands. It also reduces transvascular fluid flux and protein leakage into the airway, preventing the formation of obstructive casts in the airway that prevent adequate oxygenation. Finally, it has bronchodilating effects that reduce inherent bronchospasm arising after an inhalation injury.

There are a few limitations of this study. One is that the severity of inhalation injury was not graded in the study patients. Fiber-optic bronchoscopy is necessary for diagnosis of smoke inhalation injury. However, whether the severity of mucosal injury, as assessed through bronchoscopy, is capable of predicting clinically meaningful outcomes remains a matter of debate.³⁴ The severity can also be assessed through tomography if patients show airflow narrowing.³⁵ As there is no clear consensus on the diagnosis and grading of inhalation injury, our patients were diagnosed by bronchoscopy, which allowed us to determine whether there was any evidence of smoke inhalation injury. However, as mentioned, severity of inhalation injury was not graded. Differing injury severity likely leads to variations in the hospital course and progress of the patient. Thus, failure to classify the patients into groups with mild, moderate, or severe injuries must be taken into account when interpreting the study data because the number of ventilator days and other outcomes will be worse in patients with severe smoke inhalation injury than in those with a mild injury, regardless of the administration of nebulized epinephrine.

Other limitations of this study are the relatively small number of patients and the relatively late arrival of the patients to the burn center for care. It is well established that, in children with severe burns, early burn center transfer shortens hospital stay and decreases complications.³⁶ All patients in this study arrived within the first 96 hours post burn. This late arrival is typical because patients are referred to our hospital from all over the world and time is needed to complete necessary paperwork and arrange transport. Edema reaches its maximum in the first 48 hours post burn, so epinephrine is being started after the edema peak and this may explain why our results are not statistically significant. Given that epinephrine would be expected to be more effective when initiated right after the injury, decreasing this time from burn to epinephrine treatment may provide significant results as to its effectiveness, even if the sample size must be sacrificed.

Another limitation of the study is the non-standardized treatment that patients receive prior to their arrival. Over-resuscitation (fluid overload) can lead to pulmonary edema even in a patient with no inhalation injury. Moreover, the aggressive use of high tidal volume when ventilating a patient significantly increases the incidence of pneumothorax and the high comorbidity and risk of death that this complication imply.³⁷ A final limitation could be that the treatment was administered for only the first 7 days of hospitalization. It is possible that epinephrine has benefits when used beyond 7 days or that nebulized racemic epinephrine is most effective when administered for the entire time that the patient is on the ventilator.

Findings from this pilot study will be used to design a large-scale randomized clinical trial with the goal of translating these findings into clinical practice. Increasing the inclusion age range will extend the potential benefits to more subjects, especially infants, who have a

smaller airway diameter and are at greater risk of airway occlusion. Future studies should also examine extended treatment times and be multicenter investigations.

Acknowledgments

The authors thank Dr. Kasie Cole for editing and proofreading the manuscript, Clark R. Andersen, MS, for support in performing the statistical analyses, Julianna M. Bores for scientific support, Dr. Karel Capek for his unconditional guidance and to the team of respiratory therapists for the collaboration to perform this research.

Sources of Funding

This study was supported by the National Institutes of Health (P50 GM060338, UL1 TR000071, R01 GM056687, and R01 HD049471), the United States Department of Defense (W81XWH-12-2-0086), and Shriners Hospitals for Children (84080 and 84050).

References

1. National Burn Repository, 2015 report. American Burn Association; 2015. <http://www.ameriburn.org/2015NBRAnnualReport.pdf>
2. World Health Organization. Burns. Sep. 2016 <http://www.who.int/mediacentre/factsheets/fs365/en/>
3. Woodson, LC., Talon, M., Traber, DL., et al. Diagnosis and treatment of inhalation injury. In: Herndon, David N., editor. Total burn care. Elsevier; Saunders: p. 221-37.
4. Smith DL, Cairns BA, Ramadan F, et al. Effect of inhalation injury, burn size, and age on mortality: a study of 1447 consecutive burn patients. *J Trauma*. 1994; 37:655–9. [PubMed: 7932899]
5. Enkhbaatar P, Pruitt BA Jr, Suman O, et al. Pathophysiology, research challenges, and clinical management of smoke inhalation injury. *Lancet*. 2016; 377:1437–46.
6. Shirani KZ, Pruitt BA Jr, Mason AD Jr. The influence of inhalation injury and pneumonia on burn mortality. *Ann Surg*. 1987; 205:82–7. [PubMed: 3800465]
7. Sheridan RL. Fire-Related Inhalation Injury. *N Engl J Med*. 2016; 375:464–9. [PubMed: 27518664]
8. Enkhbaatar P, Murakami K, Shimoda K, Mizutani A, Traber L, Phillips GB, Parkinson JF, Cox R, Hawkins H, Herndon D, Traber D. The inducible nitric oxide synthase inhibitor BBS-2 prevents acute lung injury in sheep after burn and smoke inhalation injury. *Am J Respir Crit Care Med*. 2003; 167:1021–1026. [PubMed: 12663341]
9. Linares HA, Herndon DN, Traber DL. Sequence of morphologic events in experimental smoke inhalation. *J Burn Care Rehabil*. 1989 Jan-Feb;10:27–37. [PubMed: 2921256]
10. Stothert JC Jr, Ashley KD, Kramer GC, et al. Intrapulmonary distribution of bronchial blood flow after moderate smoke inhalation. *J Appl Physiol*. 1990 Nov.69:1734–9. 1985. [PubMed: 2272966]
11. Sakurai H, Johnigan R, Kikuchi Y, et al. Effect of reduced bronchial circulation on lung fluid flux after smoke inhalation in sheep. *J Appl Physiol*. 1998 Mar.84:980–6. 1985. [PubMed: 9480960]
12. Efimova O, Volokhov AB, Iliaifar S, et al. Ligation of the bronchial artery in sheep attenuates early pulmonary changes following exposure to smoke. *J Appl Physiol* 1985. 2000 Mar.88:888–93. [PubMed: 10710383]
13. Cox RA, Burke AS, Soejima K, et al. Airway obstruction in sheep with burn and smoke inhalation injuries. *Am J Respir Cell Mol Biol*. 2003 Sep.29:295–302. [PubMed: 12936906]
14. Murakami K, Traber DL. Pathophysiological basis of smoke inhalation injury. *News Physiol Sci*. 2003 Jun.18:125–9. [PubMed: 12750450]
15. Morita N, Enkhbaatar P, Maybauer DM, et al. Impact of bronchial circulation on bronchial exudates following combined burn and smoke inhalation injury in sheep. *Burns*. 2011 May. 37:465–73. DOI: 10.1016/j.burns.2010.11.005. [PubMed: 21195551]
16. Traber, DL., Herndon, DN., Enkhbaatar, P., et al. The pathophysiology of inhalation injury. In: Herndon, David N., editor. Total burn care. Elsevier; Saunders: p. 219-28.
17. Enkhbaatar P, Traber DL. Pathophysiology of acute lung injury in combined burn and smoke inhalation injury. *Clin Sci (Lond)*. 2004 Aug.107:137–43. [PubMed: 15151496]

18. Szabó C, Módis K. Pathophysiological roles of peroxynitrite in circulatory shock. *Shock*. 2010 Sep; 34(Suppl 1):4–14. DOI: 10.1097/SHK.0b013e3181e7e9ba
19. Szabó C, Ischiropoulos H, Radi R. Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. *Nat Rev Drug Discov*. 2007 Aug; 6(8):662–80. [PubMed: 17667957]
20. Westphal, TC., Westphal, DP. Adrenergic agonist and antagonists. In: Brunton, LL., editor. *Goodman&Gilman's The pharmacological basis of therapeutics*. 11. 2006. p. 237-297.
21. Lopez E, Fujiwara O, Lima F, et al. Nebulized Epinephrine Limits Pulmonary Vascular Hyperpermeability to Water and Protein in Ovine with Burn and Smoke Inhalation Injury. *Crit Care Med*. 2016; 44(2):89–96.
22. Lange M, Hamahata A, Traber DL, et al. Preclinical evaluation of epinephrine nebulization to reduce airway hyperemia and improve oxygenation after smoke inhalation injury. *Crit Care Med*. 2011 Apr; 39:718–24. DOI: 10.1097/CCM.0b013e318207ec52. [PubMed: 21263320]
23. Dhand R, Guntur VP. How Best to Deliver Aerosol Medications to Mechanically Ventilated Patients. *Clin Chest Med*. 2008; 29:277–296. [PubMed: 18440437]
24. Dolovich MB, Ahrens RC, Hess DR, Anderson P, Dhand R, et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. *Chest*. 2005 Jan; 127(1):335–71. [PubMed: 15654001]
25. Holland AE, Spruit MA, Troosters T, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. *Eur Respir J*. 2014; 44:1428–46. [PubMed: 25359355]
26. Knudson RJ, Slatin RC, Lebowitz MD, Burrows B. The maximal expiratory flow-volume curve. Normal standards, variability, and effects of age. *Am Rev Respir Dis*. 1976; 113:587–600. [PubMed: 1267262]
27. Miller <R, Hankinson J, Brusasco V, et al. Standardisation of Spirometry. *Eur Respir J*. 2005; 26(2):319–38. [PubMed: 16055882]
28. Thorax, Laszlo G. Standardization of lung function testing: helpful guidance from the ATS/ERS Task Force. 2006 Sep; 61(9):744–6.
29. Kizilarlanoglu MC, Kuyumcu ME, Yesil Y, Halil M. Sarcopenia in critically ill patients. *J Anesth*. 2016 Epub ahead of print.
30. Fry CS, Porter C, Sidossis LS, Nieten C, Reidy PT, Hundeshagen G, Mlcak R, Rasmussen BB, Lee JO, Suman OE, Herndon DN, Finnerty CC. Satellite cell activation and apoptosis in skeletal muscle from severely burned children. *J Physiol*. 2016; Epub ahead of print. doi: 10.1113/JP272520
31. Nordanstig J, Broeren M, Hensater M, et al. Six-minute walk test closely correlates to “real-life” outdoor walking capacity and quality of life in patients with intermittent claudication. *J Vasc Surg*. 2014; 60(2):404–9. [PubMed: 24690492]
32. Burtin C, Clerckx B, Robbeets C, et al. Early exercise in critically ill patients enhances short-term functional recovery. *Crit Care Med*. 2009; 37(9):2499–2505. [PubMed: 19623052]
33. Chan KS, Pfoh ER, Denehy L, et al. Construct validity and minimal important difference of 6-minute walk distance in survivors of acute respiratory failure. *Chest*. 2015; 147(5):1316–1326. [PubMed: 25742048]
34. Spano S, Hanna S, Li Z, et al. Does Bronchoscopic Evaluation of Inhalation Injury Severity Predict Outcome? *J Burn Care Res*. 2016; 37:1–11. [PubMed: 26594859]
35. Yamamura H, Morioka T, Hagawa N, et al. Computed Tomographic assessment of airflow obstruction in smoke inhalation injury. Relationship with the development of pneumonia and injury severity. *Burns*. 2015; 41(7):1428–34. [PubMed: 26187056]
36. Sheridan RL, Weber J, Prelack, et al. Early burn center transfer shortens the length of hospitalization and reduces complications in children with serious burn injuries. *J Burn Care Rehabil*. 2000; 20:347–50.
37. Sousse LE, Herndon DN, Andersen CR, et al. High tidal volume decreases adult respiratory distress syndrome, atelectasis, and ventilator days compared with low tidal volume in pediatric burned patients with inhalation injury. *J Am Coll Surg*. 2015 Apr; 220(4):570–8. DOI: 10.1016/j.jamcollsurg.2014.12.028. [PubMed: 25724604]

Table 1Patient Characteristics^a

Characteristic	Standard of Care n=8	Standard of Care Plus Epinephrine n=8	<i>p</i> value
Sex, male:female	5:3	6:2	na
Age, years	13 ± 4	11 ± 2	0.481
Height, cm	148.6 ± 19.5	144.8 ± 19.2	0.713
Weight, kg	52.3 ± 21.7	42.1 ± 14.9	0.306
TBSA burn, %	58 ± 14	49 ± 18	0.277
TBSA full-thickness burn, %	51 ± 20	43 ± 24	0.502

Abbreviations: TBSA, total body surface area.

^aValues are presented as mean ± standard deviation unless otherwise noted.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 2Length of Ventilation, Length of ICU Stay, and Six Minute Walk Test^a

Characteristic	Standard of Care n=8	Standard of Care Plus Epinephrine n=8	<i>p</i> value
Length of ventilation, days	10.1 ± 7.6	7.5 ± 5.5	0.470
Length of stay, days	55.2 ± 25.6	47.4 ± 44.4	0.687
Length of ICU stay/TBSA burn	0.9	0.9	na
Length of ICU stay/TBSA full-thickness burn	1	1	na
Six minute walk test, ft	253.5 ± 268.8	588.1 ± 384.4	0.079
Presence of pneumonia, no. (%)	50.0%	37.5%	na
Tidal volume, mL	432 ± 209	338 ± 138	0.371
Peak inspiratory pressure, mm Hg	29 ± 2	23 ± 9	0.119
Positive end expiratory pressure, mm Hg	8.0 ± 0.4	7.0 ± 2.1	0.262
Albuterol doses required in ICU, no.	6.7 ± 9.0	5.1 ± 8.0	0.748

Abbreviations: TBSA, total body surface area.

^aValues are presented as mean ± standard deviation unless otherwise noted.

Table 3Pulmonary Function Tests^a

Characteristic	Standard of Care n=8	Standard of Care Plus Epinephrine n=8	<i>p</i> value
FEV1, L	2.1 ± 0.9	2.4 ± 1.79	0.787
FEV1 % predicted	86.3 ± 85	90.6 ± 31.5	0.837
FVC, L	2.5 ± 1.2	3.1 ± 1.9	0.735
FVC % predicted	87.3 ± 9.4	97.1 ± 23	0.554
DLCO, mL/min/mm Hg	12.6 ± 4	12.7 ± 10	0.991
DLCO % predicted	74.5 ± 23	147.1 ± 114	0.692

Abbreviations: FEV1, forced expiratory volume in the first second; FVC, forced vital capacity. DLCO: Diffusing capacity of the lungs for carbon monoxide.

^aValues are presented as mean ± standard deviation.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript